Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) fell 6.4% during mid-day trading on Monday . The stock traded as low as $2.76 and last traded at $2.78, with a volume of 64,793 shares. The stock had previously closed at $2.97.

Several research firms have recently issued reports on KTOV. Rodman & Renshaw restated a “buy” rating on shares of Kitov Pharmaceuticals Holdings in a report on Saturday, May 14th. Zacks Investment Research upgraded shares of Kitov Pharmaceuticals Holdings from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a report on Wednesday, April 27th.

The firm’s 50 day moving average price is $3.60 and its 200 day moving average price is $3.96. The company’s market capitalization is $10.93 million.

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.